What’s Taking the FDA So Long?
Full approval of the vaccines could move the needle on U.S. vaccination rates. So what’s the holdup?
Listen & Subscribe
Choose your preferred player:
Apple Podcasts
Get Your Slate Plus Podcast
If you can't access your feeds, please contact customer support.
Listen on your computer:
Apple Podcasts will only work on MacOS operating systems since Catalina. We do not support Android apps on desktop at this time.
Listen on your device:RECOMMENDED
These links will only work if you're on the device you listen to podcasts on. We do not support Stitcher at this time.
Set up manually:
Episode Notes
Experts say that a “fully approved” designation for the vaccines could have sweeping effects. Broader vaccination mandates, inclusion for new age groups, and reassurance for those hesitant to take a vaccine without the designation. As calls for approval grow louder and more urgent, the Food and Drug Administration is yet to give its blessing. What’s happening inside the FDA as they work toward this milestone?
Guest: Sarah Owermohle, health care reporter at Politico
